Home > Insider Trading > Filing (0001209191-23-046246)

Filing Details

Accession Number:: 0001209191-23-046246
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-08-17 16:12:02
Reporting Period:: 2023-08-15

Accepted Time:: 2023-08-17 16:12:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1719395	Eargo Inc.	EAR	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	273879804

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1827381	William Brownie	C/O Eargo, Inc. 2665 North First Street, Suite 300 San Jose CA 95134	Interim Ceo & Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-08-17	14	$3.23	8,279	No	4	S	Direct
Common Stock	Disposition	2023-08-17	1,500	$3.20	6,779	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-08-15	112,500	$0.00	112,500	$3.31
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-08-15	93,750	$0.00	93,750	$3.31
Common Stock	Stock Option (Right to Buy)	Disposition	2023-08-15	93,750	$0.00	93,750	$11.58
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-08-15	93,750	$0.00	93,750	$3.31
Common Stock	Stock Option (Right to Buy)	Disposition	2023-08-15	93,750	$0.00	93,750	$11.58
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-08-15	825	$0.00	825	$3.31
Common Stock	Stock Option (Right to Buy)	Disposition	2023-08-15	825	$0.00	825	$1,051.60

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
112,500	2033-08-14	No	4	A	Direct
93,750	2033-01-31	No	4	A	Direct
0	2033-01-31	No	4	D	Direct
93,750	2033-01-31	No	4	A	Direct
0	2033-01-31	No	4	D	Direct
825	2031-01-28	No	4	A	Direct
0	2031-01-28	No	4	D	Direct

Footnotes

Reflects the number of shares of Common Stock that were sold to satisfy tax withholding requirements on vesting of restricted stock units pursuant to the Issuer's automatic sell to cover program, and does not represent a discretionary sale by the Reporting Person.
The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
The Issuer cancelled the Stock Option in exchange for a new Stock Option having a lower exercise price.
The Stock Option vests and becomes exercisable as to 20% of the shares subject to the stock option on February 15, 2024 (the "Vesting Start Date"), with the remainder vesting in 16 equal quarterly installments thereafter until all of the shares subject to the stock option have vested and become exercisable on the fourth anniversary of the Vesting Start Date, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, provided, that, any unvested portion of the Stock Option shall vest and become exercisable upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock, in either case, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
The Stock Option vests and becomes exercisable in full upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock on or prior to February 15, 2028, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through such date.
The Stock Option shall vest and become exercisable with respect to 16 quarterly installments commencing on February 15, 2021, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
On January 17, 2023, the Issuer effected a 1-for-20 reverse stock split of its Common Stock (the "Reverse Stock Split"). These securities reflect the Reverse Stock Split.